March 20, 2023: In a public comment, we explain our concerns about FDA’s plan to distribute user fee funding to non-governmental organizations to support premarket real world evidence (RWE).
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Statement of Dr. Diana Zuckerman, President, National Center for Health Research, March 8, 2023
Today the FDA announced that 19 women were reported in medical publications who developed squamous cell carcinoma (SCC) in the capsule around breast implants. This is more than the 10 women that FDA reported in September. Several of the women died. It is important to know that 24 cases of SCC have been reported to […]
Read More »NCHR comments on AHRQ draft review on the management of postpartum hypertensive disorders of pregnancy
NCHR agrees with AHRQ draft review designed to enhance care for women with postpartum hypertensive disorders of pregnancy. We are encouraged by the focus on the important issue of maternal mortality and look forward to seeing a meaningful response by policymakers.
Read More »NCHR Comments on USPSTF Draft Recommendation Statement Regarding Screening for Hypertensive Disorders of Pregnancy
March 6, 2023: We strongly support the US Preventive Services Task Force draft recommendations that all asymptomatic pregnant women be screened for high blood pressure throughout pregnancy. We appreciate the agency considering how screening will help prevent medical problems for mothers and babies that could be caused by hypertensive disorders of pregnancy.
Read More »Meeting of Patient, Consumer, and Public Health Coalition with Commissioner Califf and Key FDA Officials
March 1, 2023: As a leader of the Patient, Consumer, and Public Health Coalition, the National Center for Health Research scheduled a meeting at the FDA with Commissioner Califf and other key FDA officials to discuss accelerated approval, lab developed diagnostic tests, and improvements to FDA Advisory Committees.
Read More »